Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies - Journal of Thoracic Oncology
Recent advances of antibody drug conjugates for clinical applications - ScienceDirect
Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors - Moore - 2017 - Cancer - Wiley Online Library
Unlocking the potential of antibody–drug conjugates for cancer therapy | Nature Reviews Clinical Oncology
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire
NCT02631876 (Clinical Trial/ MIRVETUXIMAB SORAVTANSINE/ IMGN-853) » ADC Review
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology
Pharmacokinetic head-to-head comparison between... | Download Scientific Diagram
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
PDF) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer -
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC
Mirvetuximab soravtansine plus bevacizumab 'highly active' in ovarian cancer subset
Mirvetuximab Combos for Ovarian Cancer Showing Promise in Trials
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
SORAVTANSINE
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer | Future Oncology
Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology
